Suppr超能文献

全球根除脊髓灰质炎倡议的最新经济分析。

An Updated Economic Analysis of the Global Polio Eradication Initiative.

出版信息

Risk Anal. 2021 Feb;41(2):393-406. doi: 10.1111/risa.13665.

Abstract

Despite a strong global commitment, polio eradication efforts continue now more than 30 years after the 1988 World Health Assembly resolution that established the Global Polio Eradication Initiative (GPEI), and 20 years after the original target of the year 2000. Prior health economic analyses estimated incremental net benefits of the GPEI of 40-50 billion in 2008 U.S. dollars (US$2008, equivalent to 48-59 billion US$2019), assuming the achievement of polio eradication by 2012. Given the delays in achieving polio eradication and increased costs, we performed an updated economic analysis of the GPEI using an updated integrated global model, and considering the GPEI trajectory as of the beginning of 2020. Applying similar methods and assuming eradication achievement in 2023, we estimate incremental net benefits of the GPEI of 28 billion US$2019, which falls below the prior estimate. Delays in achieving polio eradication combined with the widescale introduction of relatively expensive inactivated poliovirus vaccine significantly increased the costs of the GPEI and make it less cost-effective, although the GPEI continues to yield expected incremental net benefits at the global level when considered over the time horizon of 1988-2029. The overall health and financial benefits of the GPEI will depend on whether and when the GPEI can achieve its goals, when eradication occurs, the valuation method applied, and the path dependence of the actions taken. Reduced expected incremental net benefits of the GPEI and the substantial economic impacts of the COVID-19 pandemic pose large financial risks for the GPEI.

摘要

尽管全球各国做出了坚定承诺,但在 1988 年世界卫生大会通过全球根除脊髓灰质炎倡议(GPEI)决议 30 多年后,以及最初设定的 2000 年根除目标 20 年后,脊髓灰质炎根除工作仍在继续。此前的卫生经济分析估计,假设到 2012 年实现根除目标,GPEI 在 2008 年(2008 年美元,相当于 480-590 亿美元)将产生 400-500 亿美元的增量净效益。鉴于根除工作的延迟和成本的增加,我们使用更新的综合全球模型对 GPEI 进行了更新的经济分析,并考虑了截至 2020 年初的 GPEI 轨迹。采用类似的方法,并假设在 2023 年实现根除,我们估计 GPEI 的增量净效益为 280 亿美元(2019 年美元),低于此前的估计。根除工作的延迟加上相对昂贵的灭活脊髓灰质炎疫苗的广泛使用,大大增加了 GPEI 的成本,使其成本效益降低,尽管从 1988 年至 2029 年的时间范围内考虑,GPEI 仍在全球范围内产生预期的增量净效益。GPEI 的总体健康和经济效益将取决于 GPEI 是否以及何时能够实现其目标、何时根除、所应用的估值方法以及所采取行动的路径依赖性。GPEI 的预期增量净效益降低以及 COVID-19 大流行的巨大经济影响给 GPEI 带来了巨大的财务风险。

相似文献

1
An Updated Economic Analysis of the Global Polio Eradication Initiative.
Risk Anal. 2021 Feb;41(2):393-406. doi: 10.1111/risa.13665.
2
Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Risk Anal. 2021 Feb;41(2):364-375. doi: 10.1111/risa.13664.
3
Economic analysis of the global polio eradication initiative.
Vaccine. 2010 Dec 16;29(2):334-43. doi: 10.1016/j.vaccine.2010.10.026. Epub 2010 Oct 26.
4
Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Risk Anal. 2021 Feb;41(2):349-363. doi: 10.1111/risa.13557. Epub 2020 Jul 9.
5
Projection of Costs of Polio Eradication Compared to Permanent Control.
J Infect Dis. 2020 Feb 3;221(4):561-565. doi: 10.1093/infdis/jiz488.
6
Polio Eradication and Endgame Plan - Victory within Grasp.
Indian Pediatr. 2016 Aug 7;53 Suppl 1:S28-S32.
7
Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Risk Anal. 2021 Feb;41(2):229-247. doi: 10.1111/risa.13484. Epub 2020 Apr 27.
8
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
Risk Anal. 2021 Feb;41(2):376-386. doi: 10.1111/risa.13614. Epub 2020 Oct 20.
9
10
The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
Vaccine. 2023 Apr 6;41 Suppl 1:A12-A18. doi: 10.1016/j.vaccine.2021.04.026. Epub 2021 Apr 27.

引用本文的文献

1
Polio Eradication in Pakistan: Innovation and Digitalization-the Key to Crossing the Finish Line.
Public Health Rev. 2025 Jan 3;45:1608084. doi: 10.3389/phrs.2024.1608084. eCollection 2024.
2
Optimum study of fractional polio model with exponential decay kernel.
Sci Rep. 2024 Jul 26;14(1):17237. doi: 10.1038/s41598-024-64611-6.
4
Can the world really stop wild polio by the end of 2023?
Nature. 2023 Aug;620(7975):706-707. doi: 10.1038/d41586-023-02577-7.
5
Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
Med Decis Making. 2023 Oct-Nov;43(7-8):850-862. doi: 10.1177/0272989X231191127. Epub 2023 Aug 14.
6
Towards the sustainable elimination of gambiense human African trypanosomiasis in Côte d'Ivoire using an integrated approach.
PLoS Negl Trop Dis. 2023 Jul 31;17(7):e0011514. doi: 10.1371/journal.pntd.0011514. eCollection 2023 Jul.
7
Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Expert Rev Vaccines. 2022 Nov;21(11):1667-1674. doi: 10.1080/14760584.2022.2128108. Epub 2022 Oct 5.
9
Polio eradication: what kind of world do we want?
Lancet Infect Dis. 2022 Feb;22(2):161-163. doi: 10.1016/S1473-3099(21)00458-8. Epub 2021 Oct 11.

本文引用的文献

1
Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
Risk Anal. 2021 Feb;41(2):364-375. doi: 10.1111/risa.13664.
3
A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
Risk Anal. 2021 Feb;41(2):376-386. doi: 10.1111/risa.13614. Epub 2020 Oct 20.
4
Valuing health outcomes: developing better defaults based on health opportunity costs.
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):729-736. doi: 10.1080/14737167.2020.1812387. Epub 2020 Sep 20.
6
Potential Future Use, Costs, and Value of Poliovirus Vaccines.
Risk Anal. 2021 Feb;41(2):349-363. doi: 10.1111/risa.13557. Epub 2020 Jul 9.
8
Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.
Risk Anal. 2021 Feb;41(2):229-247. doi: 10.1111/risa.13484. Epub 2020 Apr 27.
10
Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.
Risk Anal. 2021 Feb;41(2):248-265. doi: 10.1111/risa.13447. Epub 2020 Jan 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验